Molecular Basis of Resveratrol-Induced Resensitization of Acquired Drug-Resistant Cancer Cells.
Chul Yung ChoiSung-Chul LimTae-Bum LeeSong-Iy HanPublished in: Nutrients (2022)
Multidrug resistance (MDR) to anticancer drugs remains a serious obstacle to the success of cancer chemotherapy. Resveratrol, a polyphenol, present in natural products exerts anticancer activity and acts as a potential MDR inhibitor in various drug-resistant cancer cells. In the process of resensitization of drug-resistant cancer cells, resveratrol has been shown to interfere with ABC transporters and drug-metabolizing enzymes, increase DNA damage, inhibit cell cycle progression, and induce apoptosis and autophagy, as well as prevent the induction of epithelial to mesenchymal transition (EMT) and cancer stem cells (CSCs). This review summarizes the mechanisms by which resveratrol counteracts MDR in acquired drug-resistant cancer cell lines and provides a critical basis for understanding the regulation of MDR as well as the development of MDR-inhibiting drugs.
Keyphrases
- drug resistant
- multidrug resistant
- acinetobacter baumannii
- cell cycle
- cancer stem cells
- dna damage
- papillary thyroid
- oxidative stress
- endoplasmic reticulum stress
- cell death
- signaling pathway
- squamous cell
- cell proliferation
- epithelial mesenchymal transition
- diabetic rats
- squamous cell carcinoma
- risk assessment
- radiation therapy
- high glucose
- cell cycle arrest
- cystic fibrosis
- climate change
- stress induced